A deficiency in microsomal triglyceride transfer protein (MTP) causes the human lipoprotein deficiency syndrome abetalipoproteinemia. However, the role of MTP in the assembly and secretion of VLDL in the liver is not precisely understood. It is not clear, for instance, whether MTP is required to move the bulk of triglycerides into the lumen of the endoplasmic reticulum (ER) during the assembly of VLDL particles. To define MTP's role in hepatic lipoprotein assembly, we recently knocked out the mouse MTP gene (Mttp). Unfortunately, achieving our objective was thwarted by a lethal embryonic phenotype. In this study, we produced mice harboring a "floxed" Mttp allele and then used Cre-mediated recombination to generate liver-specific Mttp knockout mice. Inactivating the Mttp gene in the liver caused a striking reduction in VLDL triglycerides and large reductions in both VLDL/LDL and HDL cholesterol levels. The Mttp inactivation lowered apo B-100 levels in the plasma by >95% but reduced plasma apo B-48 levels by only ∼20%. Histologic studies in liver-specific knockout mice revealed moderate hepatic steatosis. Ultrastructural studies of wild-type mouse livers revealed numerous VLDL-sized lipid-staining particles within membrane-bound compartments of the secretory pathway (ER and Golgi apparatus) and few cytosolic lipid droplets. In contrast, VLDL-sized lipid-staining particles were not observed in MTPdeficient hepatocytes, either in the ER or in the Golgi apparatus, and there were numerous cytosolic fat droplets. We conclude that MTP is essential for transferring the bulk of triglycerides into the lumen of the ER for VLDL assembly and is required for the secretion of apo B-100 from the liver.
Introduction
Microsomal triglyceride transfer protein (MTP) is required for the secretion of apo B-containing lipoproteins from hepatocytes and from the absorptive enterocytes of the intestine (1, 2) . MTP is also found in other tissues where apo B-containing lipoproteins are synthesized, such as the myocardium (3, 4) , yolk sac (5) , and kidney (6) . MTP is located within the lumen of the endoplasmic reticulum (ER), where it is assumed to transfer lipids during the assembly of lipoproteins (7) . In in vitro systems, MTP transfers both neutral and polar lipids between liposomal membranes, but lipid transfer is most efficient with neutral lipids, (triglycerides and cholesterol esters). The MTP holoprotein is a heterodimer consisting of a 55-kDa multifunctional protein (protein disulfide isomerase) and a unique 97-kDa subunit. The 97-kDa subunit confers all of the lipid transfer activity to the heterodimer (8, 9) .
The importance of MTP for the secretion of apo B-containing lipoproteins was revealed in 1992, when Wetterau et al. (10) reported that both MTP activity and protein were absent in duodenal tissue of humans with abetalipoproteinemia. Abetalipoproteinemia is a recessive human disease characterized by intestinal fat malabsorption, deficiencies of fat-soluble vitamins, and a near-complete absence of apo B-containing lipoproteins (e.g., chylomicrons, VLDL, and LDL) in the plasma (11) . Abetalipoproteinemia is caused by a variety of mutations in the gene for the 97-kDa subunit of MTP (10, (12) (13) (14) .
Although human genetic studies have established the importance of MTP for the secretion of apo B-containing lipoproteins, and although in vitro studies have established that MTP can transfer lipids between liposomal membranes, the role of MTP in lipoprotein assembly and secretion has not yet been fully defined (15) . The addition of lipids to apo B during the assembly of lipoproteins is widely believed to involve 2 steps (16) (17) (18) (19) (20) (21) (22) (23) (24) . In the first step, small amounts of lipids are thought to be added to apo B as it is translated and translocated into the lumen of the rough ER, allowing apo B to fold correctly and avoid degradation. MTP is widely believed to play an important role in this first "apo B lipidation" step (1, 21, 25) . The existence of apo B in the rough ER of hepatocytes has been documented by immunoelectron microscopy (16) . However, the lipidated apo B particles cannot be seen in the rough ER by routine electron microscopy, even when the thin sections are stained for lipids, because those particles are too small (< 150 Å in diameter) and lipid poor to be resolved by this technique. In a second step, the lipidated apo B molecule is thought to acquire the bulk of its core lipids by fusing with a large, VLDL-sized, apo B-free triglyceride particle (a "second-step" particle) (17, 23) . The existence of the secondstep triglyceride particles within a special compartment of the smooth ER has been supported by 2 different electron microscopic studies (16, 23) . Biochemical studies of VLDL assembly have also supported the concept that the bulk of neutral lipids are added to apo B in a second step after its translation is complete (1, 24) .
The role, if any, of MTP in the formation of second-step lipid particles is unclear. In fact, this issue has recently been highlighted as one of the fundamental problems in understanding MTP and lipoprotein assembly (15, 26) . In recent years, several groups have tried to address this issue by performing metabolic labeling/ pulse-chase studies of lipoprotein secretion from cultured McA-RH7777 cells (a rat hepatoma cell line) in the presence of MTP inhibitor drugs, but their conclusions were very different -indeed, almost opposite. Using an MTP inhibitor drug and complex metabolic labeling protocols, one group concluded that MTP had little or no role in the addition of the bulk of lipids to nascent apo B-48-containing lipoproteins (21) . Using a similar approach and the same MTP inhibitor, another group reached the opposite conclusion -that MTP is essential for adding most of the triglycerides to apo B-containing VLDL during the second step of lipoprotein assembly (27) .
We reasoned that MTP's role, if any, in the formation of second-step lipid particles within the lumen of the smooth ER might be resolved by ultrastructural studies of lipoprotein-producing tissues that were genetically deficient in MTP. If MTP's only role in lipoprotein assembly were to lipidate the apo B molecule as it was translocated into the lumen of the rough ER (i.e., the first lipidation step), one would expect that ultrastructural studies of MTP-deficient livers would reveal normal numbers of VLDL-sized, lipid-staining, second-step particles within the lumen of the smooth ER. On the other hand, if MTP were essential for the formation of the secondstep particles, one would expect to observe a virtual absence of lipoprotein-sized particles within all membrane-bound compartments of the secretory pathway.
Initially, we thought that it would be possible to investigate MTP's role in transferring the bulk of the core lipids into the lumen of the smooth ER by generating MTP knockout mice (Mttp -/-) and then examining the livers of those mice by electron microscopy. Unfortunately, at least from the perspective of understanding hepatic lipoprotein assembly, the Mttp -/-mice died early during embryonic development (5) . To move past that roadblock, in this study we have used a conditional gene inactivation system based on Cre/loxP technology (28, 29) to generate liver-specific Mttp knockout mice. A detailed characterization of those mice, including ultrastructural studies of lipoprotein assembly, has provided fresh insights into the role of MTP in lipoprotein assembly. Figure 1a) . A neomycin-resistance cassette (neo) flanked by loxP sites ("floxed") was inserted into intron 1 of the Mttp gene. An additional loxP site was inserted upstream from the Mttp promoter and exon 1 (2.5 kb 5′ of exon 1) (Figure 1a ). All 3 loxP sites were in the same orientation. The vector was electroporated into strain 129/SvJae embryonic stem cells, and drug-resistant clones were screened by Southern blot analysis. Several targeted clones were used to generate mice harboring a mutant Mttp allele, Mttp flox , in which exon 1 was flanked by loxP sites. All of the mice had a mixed genetic background (∼50% C57BL/6 and ∼50% 129/SvJae). The mice were weaned at 21 days of age, housed in a barrier facility with a 12-hour light/12-hour dark cycle, and fed a chow diet containing 4.5% fat (Ralston Purina, St. Louis, Missouri, USA).
Methods

Generation of Mttp
Breeding Mttp flox/flox mice expressing a Cre transgene. Mttp flox/flox mice were bred with "deleter" Cre transgenic mice (30) , in which Cre is expressed in the germ cells, and Mx1-Cre transgenic mice (28, 31) . In Mx1-Cre transgenic mice, Cre expression can be induced in several tissues, including the liver, with a series of 3 intraperitoneal injections of 250 µg of polyinosinic-polycytidylic ribonucleic acid (pIpC) (Sigma Chemical Co., St. Louis, Missouri, USA) (28) .
Inactivating the Mttp gene in the liver with Cre adenovirus. The Mttp gene was inactivated in hepatocytes of Mttp flox/flox mice with an intravenous injection of 2 × 10 9 plaque-forming units of Cre adenovirus (32), as described by Rohlmann et al. (33) . The Cre adenovirus was prepared in 293 cells as previously described (34) .
RNase protection assays. To measure Mttp mRNA levels, we used an RNase protection assay (RPA) (RPA II; Ambion Inc., Austin, Texas, USA) with a 395-bp Mttp riboprobe (5). β-actin mRNA measurements were assessed with an 82-bp riboprobe at the same time, making it possible to normalize the Mttp level to the β-actin signal. Apob mRNA levels were measured by RPAs with a 245-bp Apob riboprobe (35) . Those levels were also normalized to β-actin.
Detection of apo B by Western blotting. Mouse plasma samples (1.0 µL) were size-fractionated on a 4% polyacrylamide/SDS gel, and Western blots were performed with a rabbit antiserum against mouse apo B (35) and chemiluminescence detection reagents. The intensity of apo B-48 and apo B-100 bands on the x-ray films was determined by densitometry.
Measurements of lipids and apo B-100. Cholesterol and triglyceride levels in plasma samples were measured with enzymatic assays (36, 37) . Phospholipids were measured with the phospholipid B assay (Wako Chemicals, Neuss, Germany) according to the manufacturer's protocol. The distribution of lipids in the plasma lipoprotein fractions was determined by fast-performance liquid chromatography (FPLC) (37) . The concentration of mouse apo B-100 in mouse plasma was measured with an mAb-based sandwich RIA (38) . Metabolic labeling of mouse primary hepatocytes. Primary mouse hepatocytes were prepared as described previously (39) . Hepatocytes (6 × 10 5 ) were plated onto collagen-coated 6-well tissue culture plates containing a mouse primary hepatocyte growth medium. The cells were allowed to attach for 1 hour, and the medium was removed and replaced with fresh medium containing 50 µL of [ 35 S]methionine/cysteine (Pro-Mix; 530 MBq/mL, 14.3 mCi/mL; Amersham Life Sciences, Arlington Heights, Illinois, USA). After a 3-hour incubation, the apo B in the medium was immunoprecipitated with a mouse apo B-specific antiserum (35) . The immunoprecipitates were sizefractionated on a 3-15% SDS-polyacrylamide gel. The gel was dried, and the relative amounts of 35 S incorporation into apo B-48 and apo B-100 were assessed by autoradiography. The MTP activity in primary hepatocytes was measured as described previously (7, 10) .
Histologic and ultrastructural analysis of tissues. Paraffin-embedded sections were stained with hematoxylin and eosin and periodic acid-Schiff (PAS). Frozen sections of intestinal and liver tissue were stained with oil red O and examined by light microscopy. For osmium tetroxide staining of lipids, tissue samples were embedded in epoxy resin after perfusion fixation with 1.5% glutaraldehyde, 4% polyvinylpyrrolidone (molecular weight 10,000), and 0.05% calcium chloride in 0.1 M sodium cacodylate buffer (pH 7.4). The osmium tetroxide-stained sections were counterstained with toluidine blue. Electron microscopy was performed on perfusion-fixed tissues that had been stained with the imidazole-buffered osmium tetroxide procedure (23, 40, 41) . In situ hybridization was performed as described (42) 
Results
Generating and characterizing mice with a floxed Mttp allele.
Three loxP sites, two flanking a neo in intron 1 and a third 2.5 kb upstream from exon 1, were introduced into the Mttp gene with a sequence-replacement gene-targeting vector (Figure 1a ). Two targeted clones that retained all 3 loxP sites were identified, and one was used to produce chimeric mice. The chimeras were bred to generate mice that were heterozygous for the floxed Mttp allele (Mttp flox ). The heterozygous mice (Mttp wt/flox ) were intercrossed to produce homozygotes (Mttp flox/flox ). The Mttp flox/flox mice developed normally and were healthy and fertile.
Cre recombinase deletes the DNA sequences between loxP sites when the loxP sites are in the same orientation (43) Cre-mediated recombination was also evident after the induction of Cre expression from the Mx1-Cre transgene (28) . Southern blots of pIpC-treated Mttp flox/flox /Mx1-Cre mice revealed that most of the Mttp flox alleles in the liver were converted to Mttp ∆ alleles. High levels of recombination were also noted in the spleen; lesser degrees of recombination were observed in the small intestine and heart (Figure 1d) .
Inactivating the Mttp gene in the liver. To generate mice lacking Mttp gene expression in the liver, we used 2 different approaches. First, we injected Cre adenovirus into an internal jugular vein of Mttp flox/flox mice. Second, we bred the Mx1-Cre transgene onto the background of homozygosity for the Mttp flox allele and then induced Cre expression with pIpC.
The Mttp mRNA levels were essentially identical with Mttp flox and Mttp wt alleles; in the absence of Cre, there were no statistically significant differences in Mttp mRNA levels in Mttp flox/flox and Mttp wt/wt mice, either in the intestine (not shown) or in the liver (Figure 2a) . However, when Cre expression in Mttp flox/flox /Mx1-Cre transgene mice was induced with pIpC (to generate Mttp ∆/∆ mice), Mttp mRNA levels fell by 96 ± 3% compared with those in pIpC-treated Mttp wt/wt /Mx1-Cre mice (P = 0.002) (Figure 2a) . Similarly, Mttp mRNA levels were 98 ± 3% lower in Cre adenovirus-treated Mttp flox/flox mice than in Cre adenovirus-treated Mttp wt/wt mice (P = 0.008). To test whether the Cre-induced decrease in Mttp mRNA levels resulted in a comparable reduction in MTP activity, we measured MTP activity levels in hepatocyte extracts.
Hepatic MTP activity was 97 ± 5% lower in Mttp ∆/∆ mice than in the control group (Figure 2b) . Based on the Mttp mRNA levels and MTP activity assays, as well as the Southern blots (Figure 1d ), we concluded that both the Mx1-Cre transgene and Cre adenovirus approaches inactivated the Mttp gene in the majority (>95%) of hepatocytes.
Decreased plasma lipid levels in mice lacking hepatic Mttp gene expression. As expected, the plasma lipid levels in Mttp flox/flox and Mttp wt/wt mice were similar (Table 1) . However, after pIpC induction of Cre expression in Mttp flox/flox /Mx1-Cre mice, the total plasma cholesterol levels were only 48 ± 5% of those in pIpC-treated Mttp wt/wt /Mx1-Cre mice (Table 1) . Similarly, the cholesterol levels in adenovirus-treated Mttp flox/flox mice were only 48 ± 8% of those observed in adenovirus-treated Mttp wt/wt mice. In pIpC-treated Mttp flox/flox /Mx1-Cre transgenic mice and Mttp flox/flox mice treated with Cre adenovirus, the plasma triglycerides fell by 62% and 72%, respectively. The absence of Mttp expression in the liver profoundly affected the distribution of lipids within the plasma lipoproteins ( Figure 3 ). In Mttp ∆/∆ mice, cholesterol was virtually undetectable in the VLDL and LDL fractions and was reduced by ∼50% in the HDL fraction ( Figure 3a) . The amount of triglycerides in the VLDL fraction was strikingly reduced in the Mttp ∆/∆ mice ( Figure 3b) .
The effects of hepatic Mttp gene expression on plasma apo B levels. As judged by a mAb-based RIA, apo B-100 levels fell by 99 ± 1% in the Mttp flox/flox /Mx1-Cre mice after pIpC induction but did not change in pIpC-treated Mttp wt/wt /Mx1-Cre mice ( Figure. 4a) . Apo B-100 levels were reduced to a similar extent (91 ± 5%) in Cre adenovirus-treated Mttp flox/flox mice. The striking reduction in plasma apo B-100 levels was confirmed by Western blotting (Figure 4b) .
Interestingly, the induction of hepatic MTP deficiency did not have a major effect on the plasma levels of apo B-48 ( Figure 4b) . Scanning of Western blots with a densitometer revealed that apo B-48 levels in Mttp ∆/∆ mice (n = 13) fell by 20%, a difference that was not statistically significant (P = 0.23). The plasma apo B-48 levels were variable. Occasionally, we observed animals in which the plasma apo B-48 levels were reduced by ∼50%, but we also observed many animals in which there was no change in the apo B-48 levels. Although the plasma levels of apo B-48 were reduced only moderately in Mttp ∆/∆ mice, there were striking reductions in the levels of apo B-48 in the VLDL. Using a densitometric analysis of the distribution of apo B-48 in the FPLC fractions, we found that 30% of the apo B-48 in Mttp wt/wt mice was in the VLDL fractions, while 70% was in the LDL and HDL fractions. In the Mttp ∆/∆ mice, 99.3% of the apo B-48 was in the LDL and HDL fractions and only 0.7% was in the VLDL fractions.
The fact that hepatic Mttp deficiency caused a striking reduction in the plasma levels of apo B-100, but not apo B-48, led us to consider the hypothesis that hepatic MTP deficiency might affect the secretion of apo B-100 and apo B-48 differently, i.e., that MTP might be critical for apo B-100 secretion, but less important for apo B-48 secretion. To address that hypothesis, we isolated primary hepatocytes from Mttp ∆/∆ and Mttp wt/wt mice and Normal apo B-100 mRNA levels in the livers of mice lacking hepatic Mttp gene expression. Several groups have reported elevated apo B mRNA levels in the tissues of humans with abetalipoproteinemia (44) (45) (46) , raising the possibility of feedback upregulation of apo B synthesis in the setting of diminished lipoprotein secretion. To test whether hepatic MTP deficiency truly results in an upregulation of apo B mRNA levels, we measured Apob mRNA levels in Mttp ∆/∆ and Mttp wt/wt mice with a β-actin-controlled RPA. The Apob mRNA levels in the 2 groups of mice were identical (Figure 5b) .
Accumulation of cytosolic lipid droplets in mice lacking hepatic Mttp expression.
The absence of MTP in the liver resulted in hepatic steatosis. The livers from Mttp wt/wt mice were beefy red; the livers from Mttp ∆/∆ mice were predominantly red, but had a slight yellowish hue. In osmium tetroxide-stained sections, the Mttp wt/wt hepatocytes were nearly free of intracellular lipid droplets; most of the lipid staining was confined to the vitamin A-storing Ito cells (Figure 6a ). In contrast, the vast majority of hepatocytes from Mttp ∆/∆ mice contained multiple fat droplets (Figure 6b ). Of note, an occasional hepatocyte (perhaps ∼2% of the total) appeared to be free of fat droplets; we suspect that those cells harbored an Mttp flox allele that had not been converted to an Mttp ∆ allele. The conclusion that the occasional "normal appearing" hepatocytes probably did not have an Mttp ∆/∆ genotype is supported by the Mttp mRNA assays and MTP activity assays shown in Figure 2 . Those assays revealed that we eliminated Mttp gene expression by >95%, but not by 100%. Two other histologic findings from the livers of Mttp ∆/∆ mice were noteworthy. First, staining with PAS revealed decreased amounts of glycogen in the livers of Mttp ∆/∆ mice (data not shown). Second, there was no evidence of inflammation (e.g., an infiltration of lymphocytes or neutrophils) in the livers of Mttp ∆/∆ mice (pIpCtreated Mttp flox/flox /Mx1-Cre mice) (Figure 6b ). Consistent with that observation, liver function in Mttp flox/flox /Mx1-Cre mice was normal 2 months after pIpC treatment (Table 2 ). In contrast, the serum transaminases were elevated 10 days after injection of the Cre adenovirus (Table 2) .
Limited expression of the Mx1-Cre transgene in the duodenum. The Mttp gene is expressed at high levels within the villus enterocytes of the intestine (Figure 6c ). Southern blots of intestinal DNA from pIpC-treated Mttp flox/flox /Mx1-Cre mice indicated that ∼30% of the Mttp flox alleles had been converted to Mttp ∆ alleles (Fig.  1d) . Since each intestinal villus is formed from only a few stem cells within the crypts (47, 48), we reasoned that the generation of Mttp ∆/∆ stem cells might lead to patches of fatty enterocytes on some intestinal villi. This suspicion was confirmed. In osmium tetroxide-stained sections of the duodenum from pIpC-treated Mttp flox/flox /Mx1-Cre mice, ∼20% of the villi had well-circumscribed patches of fatty enterocytes (Figure 6d and e). These patches were observed only within the lower half of the intestinal villi and never in Mttp wt/wt mice (Figure 6f) .
Ultrastructural analysis of mice lacking Mttp gene expression in the liver.
To better define the role of MTP in the assembly of lipoproteins in the liver, we analyzed liver tissue from pIpC-treated Mttp flox/flox /Mx1-Cre and Mttp wt/wt mice by electron microscopy. Each Mttp wt/wt hepatocyte contained numerous VLDL-sized lipid-staining particles in the membrane-bound compartments of the secretory pathway (e.g., smooth ER and Golgi apparatus) ( Figure  7 ). As previously described by Alexander et al. (16) , we observed that some of the lipid-staining particles in the ER were located in a terminal outpouching of that organelle. Golgi stacks and secretory vesicles in Mttp wt/wt hepatocytes were filled with large, VLDL-sized lipoproteins, typically in grapelike clusters (Figure 7) .
There was clear-cut heterogeneity in the ultrastructural appearance of hepatocytes from pIpC-treated Mttp flox/flox /Mx1-Cre mice, almost certainly because a small percentage of the cells (∼2%) had not been con-
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The verted to the Mttp ∆/∆ genotype. Relatively rare hepatocytes in these livers, perhaps 1 in 50-100, had few or no cytosolic fat droplets and somewhat smaller VLDL-sized lipoproteins in the secretory pathway ( Figure 8 ). In most Mttp ∆/∆ hepatocytes, however, there were many cytosolic lipid droplets and a complete absence of VLDL-sized lipid-staining particles in the ER and Golgi apparatus. In Figure 8 , two adjacent hepatocytes illustrate this heterogeneity: the cell on the right side of the bile canaliculus (almost certainly an Mttp ∆/∆ cell) had large, cytosolic lipid droplets and no round, VLDL-sized lipoproteins in the ER or Golgi apparatus. The cell on the left side of the bile canaliculus (likely an Mttp ∆/flox or Mttp flox/flox cell) had few or no cytosolic lipid droplets and many lipoproteins in the Golgi apparatus. Figure 9 shows an electron micrograph of a typical Mttp ∆/∆ hepatocyte. Once again, there were no VLDL-sized, lipid-staining particles in any membrane-bound structure of the secretory pathway. Although VLDL-sized, round, lipid-staining particles were virtually never observed in the secretory organelles of Mttp ∆/∆ cells, we occasionally observed small and irregularly shaped lipid-staining particulate matter within the Golgi apparatus of those cells, the nature of which is presently unknown (see arrows in Figure 9 ).
Discussion
In this study, we used Cre/loxP recombination techniques to produce mice that lack Mttp expression in the liver. Certain aspects of the phenotype of these mice (e.g., their extremely low LDL cholesterol levels) were fairly predictable, given the well-documented plasma lipid abnormalities in humans with abetalipoproteinemia (11, 15) . However, other features of MTP deficiency, particularly those related to MTP's role in lipoprotein assembly, were not as easy to predict. One of the most perplexing issues in MTP biology is whether MTP is essential for moving the bulk of neutral lipids into the lumen of the ER during the assembly of VLDL (15, 26) . In this study, we provide compelling evidence that MTP plays a critical role in the movement of triglycerides into the lumen of the ER. In the absence of MTP, VLDL-sized, round, lipid-staining particles were absent in both the ER and in the Golgi apparatus. The absence of triglycerides in the hepatocyte ER in the liver-specific Mttp knockout mice cannot be attributed to a paucity of lipids because the cytosol of those hepatocytes contained many large triglyceride droplets. The absence of VLDL-sized lipid particles in the ER broadens our conception of MTP's role in lipoprotein assembly. In addition to "lipidating" apo B as it enters the lumenal space of the ER (15, 26) , MTP is critical for moving the bulk of neutral lipids into the lumen of the smooth ER for VLDL assembly. This broader view is in apparent conflict with a prior study by Gordon et al. (21) . They used complex metabolic labeling protocols in cultured hepatoma cells to examine VLDL assembly and secretion, both in the absence and in the presence of MTP inhibitor drugs. They concluded that the addition of MTP inhibitor drugs to the cell-culture medium did not block the capacity of small and dense (d > 1.070 g/mL) apo B-48 particles to acquire a bolus of lipids, thereby transforming them into large and buoyant (d < 1.006 g/mL) VLDL. These metabolic labeling studies raised the possibility that MTP inhibitors might not block the formation of triglyceride-rich second-step particles within the ER. In view of our experiments that reveal that Mttp gene expression is required to move bulk amounts of triglycerides into the lumen of the smooth ER, how can the prior metabolic labeling studies (21) be interpreted? We do not know the answer to this question with certainty, but we suspect that the conversion of apo B-48-containing HDL to apo B-48-containing VLDL in their experiments involved the acquisition of lipids that existed in the lumen of the ER before the addition of MTP inhibitor drugs.
In our experiments, both the Cre adenovirus approach and the Mx1-Cre transgene approach inactivated Mttp gene expression in >95%, but not 100%, of hepatocytes. After the Cre expression, RNase protection assays revealed >95% reductions in Mttp mRNA levels, but trace levels of the mRNA could still be detected. Consistent with that finding, light microscopy showed occasional hepatocytes with few cytosolic fat droplets. In those "nonfatty" cells, electron microscopy revealed robust VLDL assembly. Why were we unsuccessful in inactivating both copies of the Mttp gene in all hepatocytes? We suspect that the excision of a floxed segment of DNA is a stochastic event and that rare hepatocytes either do not express Cre (perhaps because of variegation in transgene expression) or simply escape the period of high-level Cre expression without both alleles' undergoing the gene-excision event. In a few experiments, we have administered Cre adenovirus to Mttp flox/flox /Mx1-Cre mice in which Cre expression had already been induced with pIpC and found that the adenovirus further decreased Mttp gene expression (Raabe, M., et al., unpublished observations).
The plasma levels of apo B-100 and apo B-48 in the liver-specific Mttp knockout mice were intriguing. As judged by sensitive Western blots and mAb-based RIAs, the plasma levels of apo B-100 fell by 95% or more, a magnitude that was essentially identical to the decrease in Mttp mRNA levels and MTP activity levels and similar to the estimated percentage of cells containing many cytosolic fat droplets. In contrast, the plasma levels of apo B-48 were reduced by only ∼20%. Our initial reaction to these results was to conclude that we had generated "intestinal lipoprotein only" mice and that all of the apo B-48 in the plasma originated in the intestine. That supposition was based on the fact that the intestine produces only apo B-48 (49) and the assumption that we had inactivated all apo B secretion by the liver. We then recalled that the plasma apo B-48 levels in mice lacking intestinal apo B synthesis are not appreciably lower than those in control mice that do synthesize intestinal lipoproteins (41) . That observation, which indicated that most of the apo B-48 in mouse plasma originates from the liver, led us to consider an alternative explanationthat a significant amount of apo B-48 might be secreted from hepatocytes in the absence of MTP. That hypothesis was strongly supported by our experiments with Mttp ∆/∆ primary hepatocytes, which showed a large amount of apo B-48 secretion in the setting of a 98% reduction in MTP activity levels.
High levels of apo B-48 secretion by Mttp ∆/∆ hepatocytes posed a conundrum because we had demonstrated by electron microscopy that the Golgi stacks were devoid of VLDL-sized lipoproteins. One way to reconcile the absence of VLDL in the Golgi stacks with abundant apo B-48 secretion from Mttp ∆/∆ primary hepatocytes is to hypothesize that Mttp-deficient hepatocytes secrete apo B-48 on very small, dense, HDL-sized particles. While VLDL particles can be clearly viewed in the Golgi apparatus or ER in thin sections by transmission electron microscopy,
Figure 8
Electron micrograph of 2 adjoining hepatocytes from an Mttp ∆/∆ mouse (a pIpC-treated Mttp flox/flox /Mx1-Cre mouse), providing an example of the rare ultrastructural heterogeneity in hepatocytes from these mice. The cell to the right of the bile canaliculus (BC), almost certainly an Mttp ∆/∆ hepatocyte, contained numerous cytosolic lipid droplets (LD) and a complete absence of VLDL-sized, lipid-staining particles within the Golgi apparatus (G). The cell on the right of the BC was typical of >98% of hepatocytes in Mttp ∆/∆ mice. The cell to the left of the BC, likely a Mttp ∆/flox hepatocyte, had few or no cytosolic lipid droplets and small (300-550 Å) VLDL in Golgi (G) stacks (arrows) and secretory vesicles (arrowheads). We occasionally observed some irregularly shaped lipid-staining "smudges" in the Golgi stacks of Mttp ∆/∆ hepatocytes; the nature of this particulate matter is not known. Less than 2% of hepatocytes in Mttp ∆/∆ mice were similar to the cell on the left. These rare lipoprotein-producing cells almost certainly had not been converted tMttp ∆/∆ genotype. ×36,000.
HDL-sized particles are far too small (<150 Å) and cannot be clearly seen using electron microscopy. Of course, the hypothesis that Mttp ∆/∆ hepatocytes can secrete apo B-48-containing HDL, but not apo B-48-containing VLDL, is supported strongly by the virtual absence of apo B-48-containing VLDL in the plasma of Mttp ∆/∆ mice. Of note, primary mouse and rat hepatocytes normally secrete large amounts of apo B-48 in HDL-sized lipoproteins, in addition to apo B-48-containing VLDL (Veniant, M., et al., unpublished observations). Our studies suggest that these apo B-48-containing HDL-sized particles can be secreted fairly efficiently in the absence of MTP. If this proves to be the case, the effects of MTP deficiency on lipoprotein secretion would be similar to the effects of orotic acid (a pyrimidine biosynthetic intermediate). Orotic acid blocks the secretion of apo B-48-containing VLDL by interfering with the transport of lipoproteins from the ER to the Golgi apparatus, but has little effect on the secretion of apo B-48-containing HDL (50) .
To our knowledge, possibility that small and dense apo B-48 particles might be secreted from hepatocytes in the absence of MTP has never been considered previously. However, several prior observations lend credence to this scenario. First, Herscovitz et al. (51) reported apo B-41 secretion from C127 cells (a breast cancer cell line), even though those cells do not express MTP. Second, apo B-48 secretion appears to be more resistant than apo B-100 secretion to inhibition with MTP inhibitor drugs (27, 52, 53) . On the other hand, the suggestion that apo B-48 is secreted in the absence of MTP would be in conflict with earlier cell-culture studies that demonstrated that MTP expression was required for apo B secretion from cells that had been transfected with apo B-53 or apo B-41 expression vectors (54) (55) (56) . The latter experiments, however, were performed with HeLa and Cos-7 cells, which do not normally synthesize or secrete lipoproteins. That consideration may be relevant, since it is conceivable that hepatocytes express another factor (either a lipid or another protein) that might assist in the secretion of small and dense apo B-48 particles, even in the setting of MTP deficiency.
The liver-specific Mttp knockout mice have provided other lessons for understanding lipoprotein metabolism and for understanding abetalipoproteinemia. In our liver-
Figure 9
Electron micrograph of a hepatocyte from the liver of an Mttp ∆/∆ mouse, illustrating the ultrastructural characteristics of the vast majority of hepatocytes. At the ultrastructural level, the most striking feature of the Mttp ∆/∆ hepatocytes was the complete absence of VLDL-sized, lipid-staining particles within either the ER or the Golgi apparatus (G). Four Golgi complexes are imaged in this electron micrograph. The Mttp ∆/∆ hepatocytes contained numerous cytosolic lipid droplets (LD). Small and irregularly shaped lipid-staining material was occasionally observed within the Golgi cisternae (arrows). The smooth ER is widely dispersed in hepatocytes. We scrutinized more than 100 electron micrographs of Mttp ∆/∆ hepatocytes and did not observe round, VLDL-sized, lipid-staining particles in the ER. ×36,000. specific knockout mice, VLDL and HDL levels were reduced substantially. We suspect that these 2 findings are mechanistically linked, since the lipolysis of triglyceride-rich lipoproteins provides substrates for the generation of HDL (57) . In a prior study, we produced mice that lacked chylomicrons and documented a nearly identical 50% reduction in HDL cholesterol levels (41). Considered together, these studies provide a compelling argument that the liver and the intestine contribute nearly equally to the maintenance of normal plasma HDL levels. From the perspective of understanding abetalipoproteinemia, we found that the absence of MTP did not result in a compensatory upregulation of hepatic apo B mRNA levels, as had been suggested by several studies in humans (44) (45) (46) . The absence of a change in Apob mRNA levels is in keeping with the fact that apo B mRNA levels typically change very little in response to a variety of other metabolic interventions (58) .
The liver-specific Mttp knockout mice had moderate hepatic steatosis on a low-fat chow diet. One might reasonably expect the hepatic steatosis in the liver-specific knockout mice to be quite severe -perhaps more severe than that observed in humans with abetalipoproteinemia -since Mttp ∆/∆ mouse livers were required to deal with an onslaught of intestinally derived remnant lipoproteins. The livers of humans with abetalipoproteinemia, in contrast, do not face the burden of metabolizing intestinal lipoproteins. We found it intriguing that serum transaminases were normal in liver-specific Mttp knockout mice produced with the Mx1-Cre transgene approach and that the livers of those mice were devoid of any inflammatory infiltrate. These observations will probably be viewed as a hopeful sign for those interested in bringing MTP inhibitors to the marketplace as cholesterol-lowering agents (2) . However, we believe that caution is required in interpreting the absence of hepatic inflammation; we have not yet followed liver histology in the liver-specific knockout mice for a prolonged period, nor have we evaluated the possibility that the steatosis might render the liver more susceptible to inflammation in response to a second insult.
The floxed Mttp allele produced in this study should be useful for understanding other aspects of MTP biology and for studies of atherogenesis. For example, generating intestine-specific Mttp knockout mice would make it possible to define the effects of MTP deficiency in that tissue and could provide an approach for defining mechanisms for the portal absorption of long-chain fatty acids, which is thought to occur in the absence of chylomicron secretion (59) . Producing heart-specific Mttp knockout mice would provide an approach to understanding the physiologic importance of lipoprotein secretion by the myocardium (3, 4) . Tissue-specific knockout mice might also provide an approach for understanding the significance of Mttp gene expression in the ovary and testis (60) . Finally, the floxed Mttp allele provides an approach for abruptly changing LDL cholesterol levels in atherosclerosis-susceptible mice, such as the "apo B-100 only" LDL receptor-deficient mice (61) . Sudden changes in LDL levels might provide an attractive model for studying the regression of atherosclerotic lesions without resorting to dietary interventions.
While this paper was under review, another group reported the development of liver-specific MTP knockout mice (62), using a floxed "MTP" allele and Cre adenovirus. Surprisingly, they observed no effect of the liverspecific MTP knockout on the total plasma triglyceride levels. In our pIpC-treated Mttp flox/flox /Mx1-Cre mice, we observed significantly reduced plasma triglycerides. Also, they found a striking reduction in plasma apo B-48 levels, while we observed, on average, a 20% reduction. In some animals, we have occasionally observed 50% reduction in plasma apo B-48 levels, and that has generally occurred in our Cre adenovirus-treated animals. The reason for this apparent phenotypic difference is not obvious. No light or electron microscopy studies were provided in their publication.
